Premium
Metabolite signatures reflective of muscle metabolism and insulin sensitivity following a diet and fitness intervention in obese, sedentary, insulin‐resistant women
Author(s) -
Campbell Caitlin,
Chandler Carol J.,
Burnett Dustin J.,
Souza Elaine C.,
Casazza Gretchen A.,
Fiehn Oliver,
Hoppel Charles L.,
Newman John W.,
Garvey W. Timothy,
Hunter Gary R.,
Keim Nancy L.,
Fernandez Jose R.,
Adams Sean H.
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.637.9
Subject(s) - medicine , insulin , endocrinology , metabolite , insulin resistance , type 2 diabetes , insulin sensitivity , diabetes mellitus , obesity
Inefficient muscle fatty acid ß‐oxidation (FAO) is prevalent in insulin‐resistant/type 2 diabetic persons, yet no metabolite signatures of muscle‐specific FAO are available. Biomarkers of an individual's muscle FAO status would have value as indices of diabetes risk. We hypothesized that plasma metabolites reflective of dysregulated muscle FAO would be normalized in sedentary, obese, insulin‐resistant women after a diet and exercise intervention. Twelve women (BMI 33.5 ± 0.8, aged 41.7 ± 1.6 yr) completed 16 wk of moderate‐intensity physical activity with a calorie‐restricted diet, and fed defined weight‐maintenance diets during 1 wk test periods pre‐ and post‐intervention. VO 2peak increased by 11.9% (43.5 ± 1.8 to 49.4 ± 1.4 mL/kg FFM/min, P<0.0001), body weight and % body fat decreased (88.3 ± 2.4 to 82.4 ± 3.0 kg and 47.4 ± 1.1% to 43.4 ± 1.5%, respectively; P<0.001), and insulin sensivity improved (QUICKI score, 0.322 ± 0.006 to 0.338 ± 0.006, P=0.001). Blood was taken throughout a 30 min exercise bout at 45% VO 2peak , and metabolomics platforms are being applied to these samples to determine profiles of hundreds of metabolites including acylcarnitines, macronutrients and their derivatives, and oxylipins, in order to identify metabolites that track improved fitness, insulin sensitivity, and muscle FAO. Funding: USDA‐ARS Projects 5306‐51530‐016‐00D & 5306‐51530‐019‐00, and NIH‐NIDDK R01DK078328‐01